Lipids effects of PPARs by Prof. F. Sacks
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
Read MoreMAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
The exclusion of other chronic liver diseases including “excess” alcohol intake are usually necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, “positive criteria” to diagnose the disease are required. A panel of international experts from 22 countries…
Read More
From NAFLD to MAFLD: when pathophysiology succeeds
Two new position papers convincingly propose that non-alcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD). A new name for this disease affecting nearly one billion people globally is overdue, as knowledge gained from the past decades has definitely demonstrated that MAFLD is a purely metabolic disorder…
Read More